Does the media favor ZYME or MIRM?

In the previous week, Zymeworks had 3 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 7 mentions for Zymeworks and 4 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Zymeworks' score of 0.90 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZYME or PTCT more profitable?

PTC Therapeutics has a net margin of -22.58% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -126.92% -37.97% -25.31% PTC Therapeutics -22.58% -362.45% -6.76%

Does the media favor ZYME or PTCT?

In the previous week, PTC Therapeutics had 5 more articles in the media than Zymeworks. MarketBeat recorded 12 mentions for PTC Therapeutics and 7 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.90 beat PTC Therapeutics' score of 0.46 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, SRRK or ZYME?

Zymeworks has higher revenue and earnings than Scholar Rock. Zymeworks is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A Zymeworks $105.96M 16.67 -$81.13M -$1.37 N/A

Is SRRK or ZYME more profitable?

Scholar Rock has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Zymeworks -126.92% -37.97% -25.31%

Does the media refer more to SRRK or ZYME?

In the previous week, Zymeworks had 4 more articles in the media than Scholar Rock. MarketBeat recorded 7 mentions for Zymeworks and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.10 beat Zymeworks' score of 0.90 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor COGT or ZYME?

In the previous week, Zymeworks had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Zymeworks and 2 mentions for Cogent Biosciences. Zymeworks' average media sentiment score of 0.90 beat Cogent Biosciences' score of 0.45 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zymeworks 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, LNTH or ZYME?

Lantheus has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.54 $233.56M $4.15 25.93 Zymeworks $105.96M 16.67 -$81.13M -$1.37 N/A

Is LNTH or ZYME more profitable?

Lantheus has a net margin of 18.05% compared to Zymeworks' net margin of -126.92%. Lantheus' return on equity of 29.32% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Zymeworks -126.92% -37.97% -25.31%

Does the media refer more to LNTH or ZYME?

In the previous week, Lantheus and Lantheus both had 7 articles in the media. Zymeworks' average media sentiment score of 0.90 beat Lantheus' score of 0.71 indicating that Zymeworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zymeworks 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zymeworks (ZYME) Competitors

$24.19 0.00 (0.00%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$24.24 +0.05 (+0.23%)

As of 07/17/2026 04:10 PM Eastern

Compare

ZYME vs. MIRM, PTCT, SRRK, COGT, and LNTH

Should you buy Zymeworks stock or one of its competitors? MarketBeat compares Zymeworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zymeworks include Mirum Pharmaceuticals (MIRM), PTC Therapeutics (PTCT), Scholar Rock (SRRK), Cogent Biosciences (COGT), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Zymeworks compare to Mirum Pharmaceuticals?

Zymeworks (NASDAQ:ZYME) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

92.9% of Zymeworks shares are held by institutional investors. 33.5% of Zymeworks shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Zymeworks currently has a consensus price target of $37.33, indicating a potential upside of 54.33%. Mirum Pharmaceuticals has a consensus price target of $143.40, indicating a potential upside of 20.65%. Given Zymeworks' higher possible upside, equities research analysts plainly believe Zymeworks is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Zymeworks has a net margin of -126.92% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

In the previous week, Zymeworks had 3 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 7 mentions for Zymeworks and 4 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.26 beat Zymeworks' score of 0.90 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.67	-$81.13M	-$1.37	N/A
Mirum Pharmaceuticals	$521.31M	13.90	-$23.36M	-$13.61	N/A

Zymeworks has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

Summary

Zymeworks and Mirum Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Zymeworks compare to PTC Therapeutics?

Zymeworks (NASDAQ:ZYME) and PTC Therapeutics (NASDAQ:PTCT) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

PTC Therapeutics has higher revenue and earnings than Zymeworks. PTC Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.67	-$81.13M	-$1.37	N/A
PTC Therapeutics	$1.73B	3.77	$682.64M	-$2.33	N/A

PTC Therapeutics has a net margin of -22.58% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Zymeworks has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

In the previous week, PTC Therapeutics had 5 more articles in the media than Zymeworks. MarketBeat recorded 12 mentions for PTC Therapeutics and 7 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.90 beat PTC Therapeutics' score of 0.46 indicating that Zymeworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zymeworks currently has a consensus price target of $37.33, suggesting a potential upside of 54.33%. PTC Therapeutics has a consensus price target of $92.43, suggesting a potential upside of 17.61%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts clearly believe Zymeworks is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80

92.9% of Zymeworks shares are held by institutional investors. 33.5% of Zymeworks shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Zymeworks beats PTC Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Zymeworks compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Scholar Rock presently has a consensus target price of $56.00, suggesting a potential upside of 5.94%. Zymeworks has a consensus target price of $37.33, suggesting a potential upside of 54.33%. Given Zymeworks' higher possible upside, analysts clearly believe Zymeworks is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Scholar Rock has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Zymeworks has higher revenue and earnings than Scholar Rock. Zymeworks is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Zymeworks	$105.96M	16.67	-$81.13M	-$1.37	N/A

Scholar Rock has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Zymeworks	-126.92%	-37.97%	-25.31%

In the previous week, Zymeworks had 4 more articles in the media than Scholar Rock. MarketBeat recorded 7 mentions for Zymeworks and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.10 beat Zymeworks' score of 0.90 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 92.9% of Zymeworks shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Zymeworks beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Cogent Biosciences has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Zymeworks' return on equity of -37.97% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Zymeworks	-126.92%	-37.97%	-25.31%

In the previous week, Zymeworks had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Zymeworks and 2 mentions for Cogent Biosciences. Zymeworks' average media sentiment score of 0.90 beat Cogent Biosciences' score of 0.45 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Cogent Biosciences presently has a consensus target price of $45.90, suggesting a potential upside of 17.45%. Zymeworks has a consensus target price of $37.33, suggesting a potential upside of 54.33%. Given Zymeworks' higher probable upside, analysts plainly believe Zymeworks is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Zymeworks has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Zymeworks	$105.96M	16.67	-$81.13M	-$1.37	N/A

92.9% of Zymeworks shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 33.5% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Zymeworks beats Cogent Biosciences on 12 of the 15 factors compared between the two stocks.

How does Zymeworks compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Zymeworks (NASDAQ:ZYME) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 33.5% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lantheus currently has a consensus target price of $110.43, suggesting a potential upside of 2.64%. Zymeworks has a consensus target price of $37.33, suggesting a potential upside of 54.33%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts clearly believe Zymeworks is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Lantheus has a net margin of 18.05% compared to Zymeworks' net margin of -126.92%. Lantheus' return on equity of 29.32% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Zymeworks	-126.92%	-37.97%	-25.31%

In the previous week, Lantheus and Lantheus both had 7 articles in the media. Zymeworks' average media sentiment score of 0.90 beat Lantheus' score of 0.71 indicating that Zymeworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zymeworks	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.54	$233.56M	$4.15	25.93
Zymeworks	$105.96M	16.67	-$81.13M	-$1.37	N/A

Summary

Lantheus beats Zymeworks on 8 of the 15 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYME vs. The Competition

Export

Metric	Zymeworks	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.77B	$938.27M	$4.40B	$12.27B
Dividend Yield	N/A	4.84%	37.90%	9.36%
P/E Ratio	-17.66	1.50	23.70	23.92
Price / Sales	16.67	113.65	135.02	113.62
Price / Cash	N/A	22.05	30.17	48.09
Price / Book	6.74	8.62	12.18	6.18
Net Income	-$81.13M	-$3.14M	$120.21M	$331.89M
7 Day Performance	-3.01%	-2.43%	-1.22%	-1.22%
1 Month Performance	4.54%	1.89%	-1.62%	-1.30%
1 Year Performance	N/A	32.82%	11.11%	17.74%

Zymeworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYME Zymeworks	3.1373 of 5 stars	$24.19 flat	$37.33 +54.3%	N/A	$1.77B	$105.96M	N/A	460
MIRM Mirum Pharmaceuticals	3.0797 of 5 stars	$122.13 -4.4%	$143.40 +17.4%	+128.9%	$7.79B	$521.31M	N/A	140	Positive News Gap Down
PTCT PTC Therapeutics	3.3753 of 5 stars	$84.85 -5.2%	$91.57 +7.9%	+65.0%	$7.04B	$827.11M	N/A	1,410	Analyst Forecast
SRRK Scholar Rock	2.0811 of 5 stars	$56.71 -2.1%	$56.00 -1.3%	+29.8%	$6.94B	N/A	N/A	140	Positive News Gap Down
COGT Cogent Biosciences	1.7887 of 5 stars	$38.87 -4.0%	$43.73 +12.5%	+212.9%	$6.92B	N/A	N/A	80	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYME) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zymeworks (ZYME) Competitors

ZYME vs. MIRM, PTCT, SRRK, COGT, and LNTH

How does Zymeworks compare to Mirum Pharmaceuticals?

Summary

How does Zymeworks compare to PTC Therapeutics?

Summary

How does Zymeworks compare to Scholar Rock?

Summary

How does Zymeworks compare to Cogent Biosciences?

Summary

How does Zymeworks compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zymeworks (ZYME) Competitors

ZYME vs. MIRM, PTCT, SRRK, COGT, and LNTH

How does Zymeworks compare to Mirum Pharmaceuticals?

Do institutionals and insiders have more ownership in ZYME or MIRM?

Do analysts rate ZYME or MIRM?

Is ZYME or MIRM more profitable?

Does the media favor ZYME or MIRM?

Which has better earnings & valuation, ZYME or MIRM?

Which has more volatility & risk, ZYME or MIRM?

Summary

How does Zymeworks compare to PTC Therapeutics?

Which has stronger valuation & earnings, ZYME or PTCT?

Is ZYME or PTCT more profitable?

Which has more risk & volatility, ZYME or PTCT?

Does the media favor ZYME or PTCT?

Do analysts rate ZYME or PTCT?

Do institutionals and insiders hold more shares of ZYME or PTCT?

Summary

How does Zymeworks compare to Scholar Rock?

Do analysts rate SRRK or ZYME?

Which has more risk and volatility, SRRK or ZYME?

Which has better earnings and valuation, SRRK or ZYME?

Is SRRK or ZYME more profitable?

Does the media refer more to SRRK or ZYME?

Do insiders and institutionals hold more shares of SRRK or ZYME?

Summary

How does Zymeworks compare to Cogent Biosciences?

Is COGT or ZYME more profitable?

Does the media favor COGT or ZYME?

Which has more volatility and risk, COGT or ZYME?

Do analysts prefer COGT or ZYME?

Which has higher earnings and valuation, COGT or ZYME?

Do institutionals and insiders hold more shares of COGT or ZYME?

Summary

How does Zymeworks compare to Lantheus?

Which has more risk & volatility, LNTH or ZYME?

Do institutionals & insiders hold more shares of LNTH or ZYME?

Do analysts prefer LNTH or ZYME?

Is LNTH or ZYME more profitable?

Does the media refer more to LNTH or ZYME?

Which has preferable valuation and earnings, LNTH or ZYME?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools